港股通创新药ETF工银（159217）现任基金经理为刘伟琳、焦文龙。刘伟琳自2025年3月26日管理（或 拟管理）该基金，任职期内收益43.85%；焦文龙自2025年4月10日管理（或拟管理）该基金，任职期内 收益63.95%。 最新定期报告显示，工银瑞信基金（159217）重仓股包括百济神州、康方生物、信达生物、中国生物制 药、中国生物制药、石药集团、三生制药、翰森制药、科伦博泰生物-B、再鼎医药，持仓占比如下： 股票代码股票名称持仓占比持仓股数（股）持仓市值（元）06160百济神州10.84%314.54万5.89亿09926 康方生物10.77%454.20万5.86亿01801信达生物10.43%644.10万5.67亿01177中国生物制药9.82%7184.50万 5.34亿08027中国生物制药9.82%7184.50万5.34亿01093石药集团7.72%4908.40万4.20亿01530三生制药 7.41%1469.60万4.03亿03692翰森制药5.50%908.20万2.99亿06990科伦博泰生物-B3.55%41.14万1.93亿 09688再鼎医药2.79%621.62万1.5 ...

风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 港股通创新药ETF工银（159217）业绩比较基准为经汇率调整后的国证港股通创新药指数收益率，管理 人为工银瑞信基金管理有限公司，基金经理为刘伟琳、焦文龙，成立（2025-03-26）以来回报为 43.85%，近一个月回报为2.20%。 来源：新浪基金∞工作室 12月1日，港股通创新药ETF工银（159217）跌0.62%，成交额4.64亿元。当日份额减少200.00万份，最 新份额为38.65亿份，近20个交易日份额增加1.73亿份。最新资产净值计算值为55.60亿元。 ...

来源：新浪基金∞工作室 11月20日，港股通创新药ETF工银（159217）涨0.21%，成交额7.22亿元。当日份额增加8500.00万份， 最新份额为38.65亿份，近20个交易日份额增加4.45亿份。最新资产净值计算值为55.43亿元。 港股通创新药ETF工银（159217）业绩比较基准为经汇率调整后的国证港股通创新药指数收益率，管理 人为工银瑞信基金管理有限公司，基金经理为刘伟琳、焦文龙，成立（2025-03-26）以来回报为 43.42%，近一个月回报为-1.23%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 ...

来源：新浪基金∞工作室 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 港股通创新药ETF工银（159217）业绩比较基准为经汇率调整后的国证港股通创新药指数收益率，管理 人为工银瑞信基金管理有限公司，基金经理为刘伟琳、焦文龙，成立（2025-03-26）以来回报为 48.64%，近一个月回报为4.74%。 11月14日，港股通创新药ETF工银（159217）跌1.00%，成交额11.26亿元。当日份额增加4100.00万份， 最新份额为37.64亿份，近20个交易日份额增加3.41亿份。最新资产净值计算值为55.95亿元。 ...

港股通创新药ETF工银（159217）业绩比较基准为经汇率调整后的国证港股通创新药指数收益率，管理 人为工银瑞信基金管理有限公司，基金经理为刘伟琳、焦文龙，成立（2025-03-26）以来回报为 39.52%，近一个月回报为-12.41%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 来源：新浪基金∞工作室 11月4日，港股通创新药ETF工银（159217）跌2.75%，成交额7.89亿元。当日份额增加1900.00万份，最 新份额为37.11亿份，近20个交易日份额增加2.99亿份。最新资产净值计算值为51.78亿元。 ...

来源：新浪基金∞工作室 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 港股通创新药ETF工银（159217）业绩比较基准为经汇率调整后的国证港股通创新药指数收益率，管理 人为工银瑞信基金管理有限公司，基金经理为刘伟琳、焦文龙，成立（2025-03-26）以来回报为 58.14%，近一个月回报为-4.25%。 9月19日，港股通创新药ETF工银（159217）跌1.38%，成交额4.92亿元。当日份额增加100.00万份，最 新份额为33.68亿份，近20个交易日份额增加4800.00万份。最新资产净值计算值为53.26亿元。 ...

Group 1 - The ETF market showed mixed performance on the 7th, with the medical device ETF (159797) leading gains at 2.24% [2] - The Sci-Tech chip design ETF (588780) also saw an increase of 2.11%, along with the medical device index ETF (159898) which rose by 2.11% [2] - Conversely, the N-Hong Kong Stock Connect innovative drug ETF by Jiashi (520970) experienced the largest decline at 3.04%, followed by the Sci-Tech innovative drug ETF by Guotai (589720) which fell by 2.96%, and the Hong Kong Stock Connect innovative drug ETF by ICBC (159217) which dropped by 2.93% [2]

Group 1 - The Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) experienced a decline of 0.26% on August 4, with a trading volume of 845 million yuan [1] - The fund's shares decreased by 19 million to a total of 3.504 billion shares, with a reduction of 291 million shares over the last 20 trading days [1] - The latest net asset value of the fund is calculated at 5.355 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Stock Connect Innovative Drug ETF is the adjusted return of the National Index for Hong Kong Stock Connect Innovative Drugs [1] - The fund is managed by ICBC Credit Suisse Asset Management Company, with fund managers Liu Weilin and Jiao Wenlong [1] - Since its establishment on March 26, 2025, the fund has achieved a return of 52.81%, with a one-month return of 16.12% [1]

Group 1 - The core viewpoint of the news highlights the strong performance of the Hong Kong Stock Connect Innovative Drug ETF, which has achieved a 68.7% increase over the past year, ranking first among similar indices [1][3] - The ETF has seen significant trading activity, with a recent trading volume of 572 million yuan and a turnover rate of 14.22%, indicating high liquidity [1] - The upcoming 2025 American Society of Clinical Oncology (ASCO) annual meeting is expected to showcase significant advancements in cancer treatment, with a focus on innovative therapies [1][2] Group 2 - Chinese innovative drug companies are gaining international recognition, with a record number of 71 original research results presented at the ASCO meeting, indicating a growing global presence [2] - The ASCO meeting is anticipated to further update clinical data and reports, potentially increasing interest in innovative drugs [2] - The positive cycle of innovation, commercialization, and reinvestment in research is being validated, with expectations that "License out + equity cooperation" will become mainstream for international expansion [2] Group 3 - The National Index for Hong Kong Stock Connect Innovative Drugs has a low price-to-earnings ratio of 27.25, indicating a favorable valuation position [3] - The index's constituent stocks are heavily concentrated in the biopharmaceutical and chemical drug sectors, which together account for 94.2% of the index [3] - The ETF has the lowest fee rate among similar products, which reduces holding costs and enhances liquidity through T+0 trading [3]